The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness

Cancer Prevention Research

Volumn 4, Issue 12, 2011, Pages 2044-2050

  Sun, Tong ^a   Oh, William K ^a,b   Jacobus, Susanna ^a   Regan, Meredith ^a   Pomerantz, Mark ^a   Freedman, Matthew L ^a   Lee, Gwo Shu Mary ^a   Kantoff, Philip W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTRADIOL; ESTROGEN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B15; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA1 DEHYDROGENASE; TESTOSTERONE 17BETA12 DEHYDROGENASE; TESTOSTERONE 17BETA2 DEHYDROGENASE; TESTOSTERONE 17BETA3 DEHYDROGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN METABOLISM; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; GENETIC VARIABILITY; GENOTYPE; GREECE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TESTOSTERONE BLOOD LEVEL;

AGED; ANDROGENS; COHORT STUDIES; ESTRADIOL DEHYDROGENASES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GONADAL STEROID HORMONES; HAPLOTYPES; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 83055174664     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0283     Document Type: Article

References (41)

1. Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol 2010;28:4038-44.
2. Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens: history and current clinical relevance. Urology 2008;72:247-54.
3. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86-91.
4. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004;92:237-53. (Pubitemid 40128245)
5. Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 2009;73:356-61.
6. Imamoto T, Suzuki H, Utsumi T, Endo T, Takano M, Yano M, et al. Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. Future Oncol 2009;5:1005-13.
7. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer 2008;122:2345-50. (Pubitemid 351542341)
8. Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009;56:48-56.
9. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 2009;73:S4-10.
10. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102:899-911. (Pubitemid 350036930)
11. Morgentaler A, Schulman C. Testosterone and prostate safety. Front Horm Res 2009;37:197-203.
12. Hsing AW, Chu LW, Stanczyk FZ. Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev 2008;17:2525-30.
13. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1869-80.
14. Mononen N, Schleutker J. Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. J Urol 2009;181:1541-9.
15. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:969-78. (Pubitemid 46910099)
16. Lindström S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, Bälter KA, et al. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 2006;66:1729-43. (Pubitemid 44893899)
17. Travis RC, Schumacher F, Hirschhorn JN, Kraft P, Allen NE, Albanes D, et al. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 2009;18:2734-44.
18. Boger-Megiddo I, Weiss NS, Barnett MJ, Goodman GE, Chen C. V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:286-91. (Pubitemid 351272777)
19. Ahn J, Schumacher FR, Berndt SI, Pfeiffer R, Albanes D, Andriole GL, et al. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). Hum Mol Genet 2009;18:3749-57.
20. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate 2008;68:1592-8.
21. Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 2006;5:61-6.
22. D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000;284:1280-3.
23. Miller WL. Steroidogenic enzymes. Endocr Dev 2008;13:1-18.
24. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004;25:947-70. (Pubitemid 39657774)
25. Luu-The V, Bélanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:207-21. (Pubitemid 351611954)
26. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5. (Pubitemid 37033947)
27. Zabaleta J, Su LJ, LinHY, Sierra RA, Hall MC, Sartor AO, et al. Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis 2009;30:1358-62.
28. Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, et al. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev 2010;19:1871-8.
29. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, et al. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 2009;15:3223-30.
30. Sun T, Lee GS, Oh WK, Freedman ML, Pomerantz M, Pienta KJ, et al. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res 2011;17:1546-52.
31. Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52-8. (Pubitemid 32246752)
32. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, et al. The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 1997;62:148-158. (Pubitemid 27066999)
33. Mindnich R, Moller G, Adamski J. The role of 17 beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2004;218:7-20. (Pubitemid 38578426)
34. Wang JH, Tuohimaa P. Regulation of 17beta-hydroxysteroid dehydrogenase type 2, type 4 and type 5 by calcitriol, LXR agonist and 5alpha- dihydrotestosterone in human prostate cancer cells. J Steroid Biochem Mol Biol 2007;107:100-5. (Pubitemid 47362672)
35. Soronen P, Laiti M, Törn S, Härkönen P, Patrikainen L, Li Y, et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004;92:281-6. (Pubitemid 40128249)
36. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest 1999;22:110-6.
37. MacDonald AA, Herbison GP, Showell M, Farquhar CM. The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum Reprod Update 2010;16:293-311.
38. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
39. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B, Penning TM. Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem 2004;279:10784-95. (Pubitemid 38379543)
40. Hum DW, Bélanger A, Lévesque E, Barbier O, Beaulieu M, Albert C, et al. Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol 1999;69:413-23. (Pubitemid 29305564)
41. Visus C, Ito D, Dhir R, Szczepanski MJ, Chang YJ, Latimer JJ, et al. Identification of hydroxysteroid (17b) dehydrogenase type 12 (HSD17B12) as a CD8(+) T-cell-defined human tumor antigen of human carcinomas. Cancer Immunol Immunother 2011;60:919-29.